452 related articles for article (PubMed ID: 15041279)
1. A new euglobulin clot lysis assay for global fibrinolysis.
Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
[TBL] [Abstract][Full Text] [Related]
2. A new global assay of coagulation and fibrinolysis.
Goldenberg NA; Hathaway WE; Jacobson L; Manco-Johnson MJ
Thromb Res; 2005; 116(4):345-56. PubMed ID: 16038720
[TBL] [Abstract][Full Text] [Related]
3. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
4. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
5. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
6. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
7. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
8. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
10. Euglobulin lysis times: an update.
Glassman A; Abram M; Baxter G; Swett A
Ann Clin Lab Sci; 1993; 23(5):329-32. PubMed ID: 8239479
[TBL] [Abstract][Full Text] [Related]
11. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
12. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
[TBL] [Abstract][Full Text] [Related]
13. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Martínez-Zamora MA; Creus M; Tassies D; Bové A; Reverter JC; Carmona F; Balasch J
Fertil Steril; 2010 Nov; 94(6):2437-40. PubMed ID: 20378110
[TBL] [Abstract][Full Text] [Related]
14. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
15. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
16. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
17. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
[TBL] [Abstract][Full Text] [Related]
19. Effect of blood passage through the pulmonary circulation on fibrinolytic parameters.
Kloboves-Prevodnik V; Sabovic M; Keber D
Heart Vessels; 2004 Jan; 19(1):33-7. PubMed ID: 14685753
[TBL] [Abstract][Full Text] [Related]
20. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]